Industry Insights: Optogenetics pioneers win the Nobel Prize as Caribou halts allogeneic CAR‑T programs

This month’s Industry Insights leads with the 2026 Nobel Prize in Physiology or Medicine, awarded for the discovery of light-gated ion channels and optogenetics, an approach now entering clinical gene therapy for vision loss. Caribou Biosciences announced it will discontinue its allogeneic CAR-T programs, citing the financing environment, and Lakefront Biotherapeutics substantially completed its exit from cell therapy. uniQure’s AMT-130 did not reach statistical significance on its 48-month primary endpoint in Huntington’s disease, and Beam Therapeutics filed a lawsuit alleging misappropriation of its base editing trade secrets. Estuary Biotherapeutics launched with $103M, and Aspen Neuroscience filed for a Nasdaq listing.